All In Biotech

Drug Trial Radar · NCT04901117

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Multicenter Randomized Clinical Trial of 10 and 14 Days

Last checked: Nov 19, 2026Latest source record: May 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,300 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,300

Planned (sponsor's estimate)

Start

Jun 2021

Primary completion

Jun 2023

Study completion Aug 2023

Sponsor

Lead sponsor
Shandong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Affiliated Hospital of Qingdao University; The People's Hospital of Guangrao; Weihai Municipal Hospital; Shandong Province Third hospital; Taian City Central Hospital; Jining No.2 People's Hospital; Maternity and Child Care Health Center of Dezhou; Zoucheng People's Hospital; Heze Municipal 3rd people's hospital; Yuncheng Chengxin Hospital; Peking University Care Luzhong Hospital; Qihe County City Hospital; Weifang People's Hospital; Qilu Hospital of Shandong University; Shandong Electric Power Central Hospital
First posted
May 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

Conditions

  • Helicobacter Pylori Infection

Interventions

  • AmoxicillinDrug

    Use according to the drug combination options selected by each center.

  • ClarithromycinDrug

    Use according to the drug combination options selected by each center.

  • TetracyclineDrug

    Use according to the drug combination options selected by each center.

  • MetronidazoleDrug

    Use according to the drug combination options selected by each center.

  • Bismuth Potassium CitrateDrug

    Use according to the drug combination options selected by each center.

  • Colloidal Bismuth PectinDrug

    Use according to the drug combination options selected by each center.

  • Vonoprazan fumarateDrug

    Use according to the drug combination options selected by each center.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Eradication rateTime frame: Immediately after follow-up check.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Qilu hosipital

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.